CN212301578U

CN212301578U - Respiratory infectious disease detection kit

Info

Publication number: CN212301578U
Application number: CN202021207281.5U
Authority: CN
Inventors: 林晓琳; 李金鹏; 徐颖
Original assignee: Individual
Current assignee: Individual
Priority date: 2020-06-28
Filing date: 2020-06-28
Publication date: 2021-01-05
Anticipated expiration: 2030-06-28

Abstract

The utility model provides a respiratory infectious disease detection kit, which comprises a respiratory infectious disease detection reagent card, a suction pipe, a drying agent bag, a sealing bag and a diluent bottle; the sealed bag is packed with a respiratory infectious disease detection reagent card, a suction pipe and a desiccant bag; the diluent bottle is a plastic transparent dropper bottle with a cover and is filled with sterile pure water; the reagent card for detecting the respiratory infectious disease comprises a bottom plate, a cover plate and the like; the technical scheme of the utility model can be through gathering patient's venous blood or fingertip blood, and serum, plasma, whole blood detect mycoplasma, pneumonia chlamydia, adenovirus, influenza A virus, influenza B virus simultaneously, detect accurate and sensitivity and specificity height, need not join in marriage in addition instrument equipment and other reagent, make the witnessed inspections put in place one step, and is quick simple and convenient directly perceived, is suitable for and uses widely.

Description

Respiratory infectious disease detection kit

Technical Field

The utility model relates to an pass catch disease detection area, especially relate to the detection of multiple respiratory infectious diseases.

Background

Respiratory tract infection refers to infection of respiratory system such as nasal cavity, throat, trachea and bronchus of human body by pathogens. The infection of the upper respiratory tract is commonly referred to as acute upper respiratory tract infection, which is a general term for acute inflammation of nasal cavity, pharynx or throat and is the most common infectious disease of the respiratory tract. The common cause is virus, and a few are caused by bacteria. Respiratory tract infection refers to infection of respiratory system such as nasal cavity, throat, trachea and bronchus of human body by pathogens. The infection of the upper respiratory tract is commonly referred to as acute upper respiratory tract infection, which is a general term for acute inflammation of nasal cavity, pharynx or throat and is the most common infectious disease of the respiratory tract. Common causes of disease are viruses, including influenza A, influenza B, adenovirus, etc., and a few lung infections, including mycoplasma, chlamydia, etc., caused by bacteria or other pathogens.

Influenza virus, one of the common respiratory viruses, is the most rampant infectious disease in the world, and has been wrapped around the world for many times, which brings about a huge disaster to human beings. In only one major spread of influenza in 1957, 15 hundred million people all over the world develop the disease, and tens of thousands of old people and children are afflicted and killed. Adenovirus (adenoviruses) is one of the main pathogens of viral pneumonia, and infection of older children or young adults with adenovirus only causes upper respiratory tract diseases, and can cause severe acute adenovirus pneumonia in infants. Chlamydia pneumoniae (Cp) is a common human respiratory pathogen, which was first discovered in 1989. Currently, the chlamydia pneumoniae has only one serotype, the 98kD protein is a specific antigen, and the representative strain is TWAR. Chlamydia pneumoniae often causes acute respiratory infections, especially pharyngitis, sinusitis, bronchitis, pneumonia, and can induce acute attacks of bronchial asthma. Mycoplasma Pneumoniae (MP) is a common pathogen of human respiratory infections in all ages worldwide. It is the only pathogen in mycoplasma that can cause respiratory tract infection, causes upper respiratory tract infection, tracheitis, bronchitis, bronchiolitis, community-acquired pneumonia, and can aggravate bronchial asthma. MP can also cause a number of extra-pulmonary manifestations and systemic disorders such as encephalitis, guillain barre syndrome, pericarditis, arthritis, autoimmune anemia, impairment of renal function, asthma, and Crohn's disease.

Despite the wide variety of current methods for detecting respiratory pathogens, it is still very difficult to diagnose the infectious pathogen. The methods of pathogen isolation culture of bacteria and tissue cell culture of virus culture have been used as "gold standard", but are difficult to implement due to the disadvantages of complicated operation, long culture time, great technical difficulty, low positive rate, etc., and have been replaced by molecular methods in recent 10 years. With the rapid development of rapid diagnosis technology, the molecular detection technology is more perfect and has been used as a new standard for detecting respiratory pathogens, but the molecular detection technology cannot be popularized due to high requirements on laboratory conditions, and the commercial products are few, do not form a series, and most pathogens cannot be detected yet. In recent years, development of immunological techniques, particularly wide application of immunological labeling techniques, such as direct and indirect immunofluorescence, and anti-alkaline phosphatase bridging enzyme labeling, has led to development and application of methods for detecting respiratory pathogens using immunofluorescence, but the techniques still have many disadvantages: the detection and analysis technical program is complex, the requirement on the professional technical level of operators is high, the time consumption for the joint inspection of various pathogens is long, and the operation is complicated. At present, an indirect and direct immunofluorescence antibody method (IFA/DFA) can be combined into a multi-joint detection form, an agency at home imports an immunofluorescence method detection reagent of VIRCELL company of Spanish, can simultaneously detect 9 respiratory tract pathogen antibodies for clinical auxiliary diagnosis, but the method also has the defects of complicated operation steps, high requirements on professional level and clinical experience of operators, the need of using a precise operation electron microscope for observation, the need of using a fluorescence detector and the like, which cannot be directly used in outpatients.

The existing means (such as culture method, PCR, ELISA, immunofluorescence method and the like) for detecting respiratory pathogens are complex to operate, time-consuming, labor-consuming and special instruments are needed, so that the existing means is not favorable for wide clinical application. The colloidal gold immunochromatography method has the advantages of short detection time, good stability, simple and convenient operation, no need of other instruments and equipment, and suitability for on-site rapid diagnosis, but at present, a multifunctional detection card for detecting common respiratory pathogens such as influenza A virus, influenza B virus, adenovirus, mycoplasma and chlamydia at the same time does not exist. If the upper respiratory tract infection caused by any pathogen cannot be effectively distinguished, doctors cannot accurately take the medicine, for example, the medicine for treating the hepatitis A and B is antiviral such as oseltamivir, symptomatic treatment or hormone treatment is adopted for treating adenovirus infection, and antibiotics such as azithromycin is adopted for treating mycoplasma chlamydia infection. In view of this, the present invention is especially provided.

SUMMERY OF THE UTILITY MODEL

In view of the above-mentioned shortcomings of the prior art, the present invention provides a kit for simultaneously detecting multiple respiratory infectious diseases. In order to overcome the defects of complex detection means, long detection time and high price at present, the utility model discloses the well principle adopts colloidal gold liquid chromatography technique, establishes a respiratory infectious disease detection kit.

In order to achieve the above and other related objects, the present invention provides a respiratory infectious disease detection kit, which comprises a respiratory infectious disease detection reagent card, a suction tube, a desiccant bag, a sealing bag, and a diluent bottle; the sealed bag is packed with a respiratory infectious disease detection reagent card, a suction pipe and a desiccant bag; the diluent bottle is a plastic transparent dropper bottle with a cover and is filled with sterile pure water; the respiratory infectious disease detection reagent card comprises a bottom plate, a cover plate, a mycoplasma pneumoniae detection card, a chlamydia pneumoniae detection card, an adenovirus detection card, an influenza A virus detection card, an influenza B virus detection card, a sample pad, a mycoplasma pneumoniae colloidal gold combination pad, a chlamydia pneumoniae colloidal gold combination pad, an adenovirus colloidal gold combination pad, an influenza A virus colloidal gold combination pad and an influenza B virus colloidal gold combination pad; the cover plate and the bottom plate are buckled with each other, and the internal space between the cover plate and the bottom plate is used for placing a mycoplasma pneumoniae detection card, a chlamydia pneumoniae detection card, an adenovirus detection card, an influenza A virus detection card, an influenza B virus detection card, a sample pad, a mycoplasma inflammation colloidal gold combination pad, a chlamydia pneumoniae colloidal gold combination pad, an adenovirus colloidal gold combination pad, an influenza A virus colloidal gold combination pad and an influenza B virus colloidal gold combination pad; the mycoplasma pneumoniae detection card, the chlamydia pneumoniae detection card, the adenovirus detection card, the influenza A virus detection card, the influenza B virus detection card, the sample pad, the mycoplasma pneumoniae colloidal gold bonding pad, the chlamydia pneumoniae colloidal gold bonding pad, the adenovirus colloidal gold bonding pad, the influenza A virus colloidal gold bonding pad and the influenza B virus colloidal gold bonding pad are fixed on the bottom plate; the cover plate is provided with a sample adding window, a mycoplasma pneumoniae detection window, a chlamydia pneumoniae detection window, an adenovirus detection window, an influenza A virus detection window and an influenza B virus detection window; the sample adding window is a circular window; the sample pad is arranged below the sample adding window; the sample pad is respectively connected with the mycoplasma pneumoniae colloidal gold combination pad, the chlamydia pneumoniae colloidal gold combination pad, the adenovirus colloidal gold combination pad, the influenza A virus colloidal gold combination pad and the influenza B virus colloidal gold combination pad; an MP word is arranged beside the Mycoplasma pneumoniae detection window, and a Mycoplasma pneumoniae detection card is arranged below the MP word; a CP character is arranged beside the detection window of the chlamydia pneumoniae, and a detection card of the chlamydia pneumoniae corresponds to the lower part of the detection window; an Ad word is arranged beside the adenovirus detection window, and an adenovirus detection card is arranged below the Ad word; a FluA word is arranged beside the influenza A virus detection window, and the lower part of the FluA word corresponds to an influenza A virus detection card; a FluB character is arranged beside the influenza B virus detection window, and the lower part of the FluB character corresponds to an influenza B virus detection card; the pneumonia mycoplasma detection card, the pneumonia chlamydia detection card, the adenovirus detection card, the influenza A virus detection card and the influenza B virus detection card are all composed of a nitrocellulose membrane, a water absorption pad, a detection line T line and a quality control line C line; the nitrocellulose membrane and the water absorption pad are sequentially connected; the detection line T line and the quality control line C line are positioned on the nitrocellulose membrane, and the quality control line C line is close to the water absorption pad; the mycoplasma pneumoniae detection card, the chlamydia pneumoniae detection card, the adenovirus detection card, the influenza A virus detection card and the influenza B virus detection card are respectively connected with the mycoplasma pneumoniae colloidal gold combination pad, the chlamydia pneumoniae colloidal gold combination pad, the adenovirus colloidal gold combination pad, the influenza A virus colloidal gold combination pad and the influenza B virus colloidal gold combination pad.

Preferably, the control line C on the Mycoplasma pneumoniae detection card is coated with a mouse anti-Mycoplasma pneumoniae monoclonal antibody, the detection line T is coated with a Mycoplasma pneumoniae antigen, and the Mycoplasma pneumoniae colloidal gold conjugate pad is coated with a colloidal gold-labeled Mycoplasma pneumoniae antigen.

Preferably, the control line C on the chlamydia pneumoniae detection card is coated with a chlamydia pneumoniae IgG antibody, the detection line T is coated with a mouse anti-human IgG, and the chlamydia pneumoniae colloidal gold binding pad is coated with a colloidal gold-labeled recombinant chlamydia pneumoniae antigen.

Preferably, the quality control line C on the adenovirus detection card is coated with an adenovirus IgM antibody, the detection line T is coated with a mouse anti-human IgG, and the adenovirus colloidal gold binding pad is coated with a colloidal gold-labeled adenovirus antigen.

Preferably, the influenza A virus detection card is provided with a quality control line C coated with an influenza A virus monoclonal antibody, a detection line T coated with a mouse anti-human IgG, and the influenza A virus colloidal gold binding pad coated with a colloidal gold-labeled influenza A virus antigen.

Preferably, the quality control line C on the influenza B virus detection card is coated with an influenza B virus monoclonal antibody, the detection line T is coated with mouse anti-human IgG, and the influenza B virus colloidal gold conjugate pad is coated with a colloidal gold-labeled influenza B virus antigen.

As mentioned above, the utility model discloses a respiratory infectious disease detect reagent box, when using, just can directly use in the outpatient service, can gather patient's venous blood or fingertip blood, serum, plasma, whole blood all can, detect accurate and advantage obvious, at first the utility model discloses the reagent box sensitivity and the specificity of invention are high, and it is unanimous with the immunofluorescence assay detection reagent detection qualification rate of VIRCELL company; the second operation is simple, convenient and quick, the detection of five respiratory pathogens can be realized by one-time sample adding, the defect of low flux of conventional single detection is overcome, and the detection efficiency is improved; the third result is visual in shape and convenient to observe, can be interpreted only through the color change of the detection line and the quality control line, and can be operated by a doctor or a nurse in an outpatient service; the fourth detection cost is low, the investment is small, and the kit of the invention is used without additionally arranging instruments and equipment and other reagents, so that the site detection can be completed in one step.

Drawings

FIG. 1 is a schematic view of the respiratory infectious disease detection kit of the present invention.

Fig. 2 is a schematic view of the reagent card for detecting respiratory infectious disease according to the present invention.

Fig. 3 is a schematic view showing the top view of the reagent card for detecting respiratory infectious disease according to the present invention.

Description of reference numerals: respiratory tract infectious disease detection reagent card 1, suction tube 2, drying agent bag 3, sealing bag 4, diluent bottle 5, bottom plate 6, cover plate 7, mycoplasma pneumoniae detection card 8, chlamydia pneumoniae detection card 9, adenovirus detection card 10, influenza a virus detection card 11, influenza b virus detection card 12, sample pad 13, mycoplasma pneumoniae colloidal gold conjugate pad 14, chlamydia pneumoniae colloidal gold conjugate pad 15, adenovirus colloidal gold conjugate pad 16, influenza a virus colloidal gold conjugate pad 17, influenza b virus colloidal gold conjugate pad 18, sample application window 19, mycoplasma pneumoniae detection window 20, chlamydia pneumoniae detection window 21, adenovirus detection window 22, influenza a virus detection window 23, influenza b virus detection window 24, cellulose nitrate membrane 25, water absorption pad 26, detection line T line 27 and quality control line C line 28.

Detailed Description

Example 1

In the description of the present invention, it should be noted that, unless otherwise explicitly specified or limited, the terms "snap" or "mount" or "connect" should be interpreted broadly, e.g., as a fixed connection, a detachable connection, or an integral connection; they may be mechanically or electrically connected, directly or indirectly through intervening media, or may be interconnected between two elements. The specific meaning of the above terms in the present invention can be understood by those of ordinary skill in the art through specific situations.

As shown in fig. 1 to 3, the utility model provides a respiratory infectious disease detection kit, which comprises a respiratory infectious disease detection reagent card, a suction tube, a desiccant bag, a sealing bag and a diluent bottle; the sealed bag is packed with a respiratory infectious disease detection reagent card, a suction pipe and a desiccant bag; the diluent bottle is a plastic transparent dropper bottle with a cover and is filled with sterile pure water; the respiratory infectious disease detection reagent card comprises a bottom plate, a cover plate, a mycoplasma pneumoniae detection card, a chlamydia pneumoniae detection card, an adenovirus detection card, an influenza A virus detection card, an influenza B virus detection card, a sample pad, a mycoplasma pneumoniae colloidal gold combination pad, a chlamydia pneumoniae colloidal gold combination pad, an adenovirus colloidal gold combination pad, an influenza A virus colloidal gold combination pad and an influenza B virus colloidal gold combination pad; the cover plate and the bottom plate are buckled with each other, and the internal space between the cover plate and the bottom plate is used for placing a mycoplasma pneumoniae detection card, a chlamydia pneumoniae detection card, an adenovirus detection card, an influenza A virus detection card, an influenza B virus detection card, a sample pad, a mycoplasma inflammation colloidal gold combination pad, a chlamydia pneumoniae colloidal gold combination pad, an adenovirus colloidal gold combination pad, an influenza A virus colloidal gold combination pad and an influenza B virus colloidal gold combination pad; the mycoplasma pneumoniae detection card, the chlamydia pneumoniae detection card, the adenovirus detection card, the influenza A virus detection card, the influenza B virus detection card, the sample pad, the mycoplasma pneumoniae colloidal gold bonding pad, the chlamydia pneumoniae colloidal gold bonding pad, the adenovirus colloidal gold bonding pad, the influenza A virus colloidal gold bonding pad and the influenza B virus colloidal gold bonding pad are fixed on the bottom plate; the cover plate is provided with a sample adding window, a mycoplasma pneumoniae detection window, a chlamydia pneumoniae detection window, an adenovirus detection window, an influenza A virus detection window and an influenza B virus detection window; the sample adding window is a circular window; the sample pad is arranged below the sample adding window; the sample pad is respectively connected with the mycoplasma pneumoniae colloidal gold combination pad, the chlamydia pneumoniae colloidal gold combination pad, the adenovirus colloidal gold combination pad, the influenza A virus colloidal gold combination pad and the influenza B virus colloidal gold combination pad; an MP word is arranged beside the Mycoplasma pneumoniae detection window, and a Mycoplasma pneumoniae detection card is arranged below the MP word; a CP character is arranged beside the detection window of the chlamydia pneumoniae, and a detection card of the chlamydia pneumoniae corresponds to the lower part of the detection window; an Ad word is arranged beside the adenovirus detection window, and an adenovirus detection card is arranged below the Ad word; a FluA word is arranged beside the influenza A virus detection window, and the lower part of the FluA word corresponds to an influenza A virus detection card; a FluB character is arranged beside the influenza B virus detection window, and the lower part of the FluB character corresponds to an influenza B virus detection card; the pneumonia mycoplasma detection card, the pneumonia chlamydia detection card, the adenovirus detection card, the influenza A virus detection card and the influenza B virus detection card are all composed of a nitrocellulose membrane, a water absorption pad, a detection line T line and a quality control line C line; the nitrocellulose membrane and the water absorption pad are sequentially connected; the detection line T line and the quality control line C line are positioned on the nitrocellulose membrane, and the quality control line C line is close to the water absorption pad; the mycoplasma pneumoniae detection card, the chlamydia pneumoniae detection card, the adenovirus detection card, the influenza A virus detection card and the influenza B virus detection card are respectively connected with a mycoplasma pneumoniae colloidal gold combination pad, a chlamydia pneumoniae colloidal gold combination pad, an adenovirus colloidal gold combination pad, an influenza A virus colloidal gold combination pad and an influenza B virus colloidal gold combination pad; a quality control line C on the mycoplasma pneumoniae detection card is coated with a mouse mycoplasma pneumoniae-resistant monoclonal antibody, a detection line T is coated with a mycoplasma pneumoniae antigen, and the mycoplasma pneumoniae colloidal gold binding pad is coated with a colloidal gold-labeled mycoplasma pneumoniae antigen; a quality control line C on the chlamydia pneumoniae detection card is coated with a chlamydia pneumoniae IgG antibody, a detection line T is coated with a mouse anti-human IgG, and the chlamydia pneumoniae colloidal gold bonding pad is coated with a recombinant chlamydia pneumoniae antigen marked by colloidal gold; the quality control line C on the adenovirus detection card is coated with an adenovirus IgM antibody, the detection line T is coated with a mouse anti-human IgG, and the adenovirus colloidal gold binding pad is coated with an adenovirus antigen marked by colloidal gold; the quality control line C on the influenza A virus detection card is coated with an influenza A virus monoclonal antibody, the detection line T is coated with mouse anti-human IgG, and the influenza A virus colloidal gold binding pad is coated with an influenza A virus antigen marked by colloidal gold; the quality control line C on the influenza B virus detection card is wrapped by an influenza B virus monoclonal antibody, the detection line T is wrapped by mouse anti-human IgG, and the influenza B virus colloidal gold conjugate pad is wrapped by a colloidal gold-labeled influenza B virus antigen.

Example 2

The utility model provides a respiratory infectious disease detection kit, the composition structure is as described in embodiment 1; when in use, the sealing bag is opened, a respiratory infectious disease detection reagent card and a suction tube are taken out, venous blood or fingertip blood can be extracted from a patient, 10 to 15 drops of the reagent card are directly dripped into a sample adding hole when serum or plasma is used, and the sample adding hole is kept stand for about 5 to 10 minutes; when the whole blood is used, 5-8 drops of the whole blood are dripped into the sample adding hole, 5 drops of diluent is dripped into the sample adding hole, and the mixture is kept stand for 5-10 minutes; and (3) observing whether the quality control line C appears in each detection window, if the quality control line C does not appear or appears after more than half an hour, invalidating the result, detecting again, and if the quality control line C appears, recording the result of the detection line T as positive detection of the corresponding pathogen.

The above description is only for the specific embodiments of the present invention, but the protection scope of the present invention is not limited thereto, and any person skilled in the art can be covered within the protection scope of the present invention without the changes or substitutions thought by the inventive work within the technical scope of the present invention. Therefore, the protection scope of the present invention should be subject to the protection scope defined by the claims.

Claims

1. The respiratory infectious disease detection kit is characterized by comprising a respiratory infectious disease detection reagent card, a suction pipe, a drying agent bag, a sealing bag and a diluent bottle; the sealed bag is packed with a respiratory infectious disease detection reagent card, a suction pipe and a desiccant bag; the diluent bottle is a plastic transparent dropper bottle with a cover and is filled with sterile pure water; the respiratory infectious disease detection reagent card comprises a bottom plate, a cover plate, a mycoplasma pneumoniae detection card, a chlamydia pneumoniae detection card, an adenovirus detection card, an influenza A virus detection card, an influenza B virus detection card, a sample pad, a mycoplasma pneumoniae colloidal gold combination pad, a chlamydia pneumoniae colloidal gold combination pad, an adenovirus colloidal gold combination pad, an influenza A virus colloidal gold combination pad and an influenza B virus colloidal gold combination pad; the cover plate and the bottom plate are buckled with each other, and the internal space between the cover plate and the bottom plate is used for placing a mycoplasma pneumoniae detection card, a chlamydia pneumoniae detection card, an adenovirus detection card, an influenza A virus detection card, an influenza B virus detection card, a sample pad, a mycoplasma inflammation colloidal gold combination pad, a chlamydia pneumoniae colloidal gold combination pad, an adenovirus colloidal gold combination pad, an influenza A virus colloidal gold combination pad and an influenza B virus colloidal gold combination pad; the mycoplasma pneumoniae detection card, the chlamydia pneumoniae detection card, the adenovirus detection card, the influenza A virus detection card, the influenza B virus detection card, the sample pad, the mycoplasma pneumoniae colloidal gold bonding pad, the chlamydia pneumoniae colloidal gold bonding pad, the adenovirus colloidal gold bonding pad, the influenza A virus colloidal gold bonding pad and the influenza B virus colloidal gold bonding pad are fixed on the bottom plate; the cover plate is provided with a sample adding window, a mycoplasma pneumoniae detection window, a chlamydia pneumoniae detection window, an adenovirus detection window, an influenza A virus detection window and an influenza B virus detection window; the sample adding window is a circular window; the sample pad is arranged below the sample adding window; the sample pad is respectively connected with the mycoplasma pneumoniae colloidal gold combination pad, the chlamydia pneumoniae colloidal gold combination pad, the adenovirus colloidal gold combination pad, the influenza A virus colloidal gold combination pad and the influenza B virus colloidal gold combination pad; an MP word is arranged beside the Mycoplasma pneumoniae detection window, and a Mycoplasma pneumoniae detection card is arranged below the MP word; a CP character is arranged beside the detection window of the chlamydia pneumoniae, and a detection card of the chlamydia pneumoniae corresponds to the lower part of the detection window; an Ad word is arranged beside the adenovirus detection window, and an adenovirus detection card is arranged below the Ad word; a FluA word is arranged beside the influenza A virus detection window, and the lower part of the FluA word corresponds to an influenza A virus detection card; a FluB character is arranged beside the influenza B virus detection window, and the lower part of the FluB character corresponds to an influenza B virus detection card; the pneumonia mycoplasma detection card, the pneumonia chlamydia detection card, the adenovirus detection card, the influenza A virus detection card and the influenza B virus detection card are all composed of a nitrocellulose membrane, a water absorption pad, a detection line T line and a quality control line C line; the nitrocellulose membrane and the water absorption pad are sequentially connected; the detection line T line and the quality control line C line are positioned on the nitrocellulose membrane, and the quality control line C line is close to the water absorption pad; the mycoplasma pneumoniae detection card, the chlamydia pneumoniae detection card, the adenovirus detection card, the influenza A virus detection card and the influenza B virus detection card are respectively connected with the mycoplasma pneumoniae colloidal gold combination pad, the chlamydia pneumoniae colloidal gold combination pad, the adenovirus colloidal gold combination pad, the influenza A virus colloidal gold combination pad and the influenza B virus colloidal gold combination pad.

2. The respiratory infectious disease detection kit according to claim 1, characterized in that: a quality control line C on the mycoplasma pneumoniae detection card is coated with a mouse mycoplasma pneumoniae-resistant monoclonal antibody, a detection line T is coated with a mycoplasma pneumoniae antigen, and the mycoplasma pneumoniae colloidal gold binding pad is coated with a colloidal gold-labeled mycoplasma pneumoniae antigen.

3. The respiratory infectious disease detection kit according to claim 1, characterized in that: a quality control line C on the chlamydia pneumoniae detection card is coated with a chlamydia pneumoniae IgG antibody, a detection line T is coated with a mouse anti-human IgG, and the chlamydia pneumoniae colloidal gold bonding pad is coated with a recombinant chlamydia pneumoniae antigen marked by colloidal gold.

4. The respiratory infectious disease detection kit according to claim 1, characterized in that: the quality control line C on the adenovirus detection card is coated with an adenovirus IgM antibody, the detection line T is coated with a mouse anti-human IgG, and the adenovirus colloidal gold binding pad is coated with a colloidal gold-labeled adenovirus antigen.

5. The respiratory infectious disease detection kit according to claim 1, characterized in that: a quality control line C on the influenza A virus detection card is coated with an influenza A virus monoclonal antibody, a detection line T is coated with mouse anti-human IgG, and the influenza A virus colloidal gold combined pad is coated with a colloidal gold-labeled influenza A virus antigen.

6. The respiratory infectious disease detection kit according to claim 1, characterized in that: the quality control line C on the influenza B virus detection card is wrapped by an influenza B virus monoclonal antibody, the detection line T is wrapped by mouse anti-human IgG, and the influenza B virus colloidal gold conjugate pad is wrapped by a colloidal gold-labeled influenza B virus antigen.